A drug development perspective on targeting tumor-associated myeloid cells

FEBS Journal

Volumn 285, Issue 4, 2018, Pages 763-776

  Majety, Meher ^a   Runza, Valeria ^a   Lehmann, Christian ^a   Hoves, Sabine ^a   Ries, Carola H ^a  

^a ROCHE INNOVATION CENTER MUNICH   (Germany)

Author keywords

CCL2; CD40; CD47; CSF 1R; depletion; reprogramming; trabectedin; tumor microenvironment; tumor associated macrophages; tumor associated myeloid cells

Indexed keywords

CD47 ANTIGEN; CHEMOKINE RECEPTOR CCR2; COLONY STIMULATING FACTOR 1; COLONY STIMULATING FACTOR 1 INHIBITOR; COLONY STIMULATING FACTOR RECEPTOR; COLONY STIMULATING FACTOR RECEPTOR 1 INHIBITOR; CP 870893; ENZYME INHIBITOR; MACROPHAGE DERIVED CHEMOKINE; PHOSPHATIDYLINOSITOL 3 KINASE GAMMA INHIBITOR; PROTEIN INHIBITOR; REGULATOR PROTEIN; SIGNAL REGULATORY PROTEIN ALPHA; TRABECTEDIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC ACTIVITY; BONE MARROW CELL; CANCER PROGNOSIS; CELL FUNCTION; CELL SELECTION; CLINICAL EVALUATION; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG TOLERABILITY; HEALTH PROGRAM; HUMAN; NONHUMAN; NUCLEAR REPROGRAMMING; OVARY CANCER; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTEIN TARGETING; REVIEW; SOFT TISSUE SARCOMA; TARGET CELL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL; CHEMISTRY; DRUG EFFECT; METABOLISM; NEOPLASM; PATHOLOGY; SYNTHESIS;

ANTINEOPLASTIC AGENTS; DRUG DEVELOPMENT; HUMANS; MYELOID CELLS; NEOPLASMS;

EID: 85031712554     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/febs.14277     Document Type: Review

References (101)

1. Murray PJ & Wynn TA (2011) Protective and pathogenic functions of macrophage subsets. Nat Rev Immunol 11, 723–737.
2. Sica A & Mantovani A (2012) Macrophage plasticity and polarization: in vivo veritas. J Clin Invest 122, 787–795.
3. Binnemars-Postma K, Storm G & Prakash J (2017) Nanomedicine strategies to target tumor-associated macrophages. Int J Mol Sci 18, pii: E979. https://doi.org/10.3390/ijms18050979
4. Brown JM, Recht L & Strober S (2017) The promise of targeting macrophages in cancer therapy. Clin Cancer Res 23, 3241–3250.
5. Mantovani A, Marchesi F, Malesci A, Laghi L & Allavena P (2017) Tumour-associated macrophages as treatment targets in oncology. Nat Rev Clin Oncol 14, 399–416.
6. Ngambenjawong C, Gustafson HH & Pun SH (2017) Progress in tumor-associated macrophage (TAM)-targeted therapeutics. Adv Drug Deliv Rev 114, 206–221.
7. Bingle L, Brown NJ & Lewis CE (2002) The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol 196, 254–265.
8. Colvin EK (2014) Tumor-associated macrophages contribute to tumor progression in ovarian cancer. Front Oncol 4, 137.
9. Xu L, Zhu Y, Chen L, An H, Zhang W, Wang G, Lin Z & Xu J (2014) Prognostic value of diametrically polarized tumor-associated macrophages in renal cell carcinoma. Ann Surg Oncol 21, 3142–3150.
10. Zhang QW, Liu L, Gong CY, Shi HS, Zeng YH, Wang XZ, Zhao YW & Wei YQ (2012) Prognostic significance of tumor-associated macrophages in solid tumor: a meta-analysis of the literature. PLoS One 7, e50946.
11. Martinez FO & Gordon S (2014) The M1 and M2 paradigm of macrophage activation: time for reassessment. F1000Prime Rep, 6, 13.
12. Murray PJ, Allen JE, Biswas SK, Fisher EA, Gilroy DW, Goerdt S, Gordon S, Hamilton JA, Ivashkiv LB, Lawrence T et al. (2014) Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity 41, 14–20.
13. Kumar V, Patel S, Tcyganov E & Gabrilovich DI (2016) The nature of myeloid-derived suppressor cells in the tumor microenvironment. Trends Immunol 37, 208–220.
14. Marvel D & Gabrilovich DI (2015) Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected. J Clin Invest 125, 3356–3364.
15. Biswas SK & Mantovani A (2010) Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol 11, 889–896.
16. Ruffell B & Coussens LM (2015) Macrophages and therapeutic resistance in cancer. Cancer Cell 27, 462–472.
17. Bronte V & Murray PJ (2015) Understanding local macrophage phenotypes in disease: modulating macrophage function to treat cancer. Nat Med 21, 117–119.
18. Audran R, Lesimple T, Delamaire M, Picot C, Van Damme J & Toujas L (1996) Adhesion molecule expression and response to chemotactic agents of human monocyte-derived macrophages. Clin Exp Immunol 103, 155–160.
19. Chitu V & Stanley ER (2006) Colony-stimulating factor-1 in immunity and inflammation. Curr Opin Immunol 18, 39–48.
20. Bronte V, Brandau S, Chen SH, Colombo MP, Frey AB, Greten TF, Mandruzzato S, Murray PJ, Ochoa A, Ostrand-Rosenberg S et al. (2016) Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nat Commun 7, 12150.
21. Coffelt SB, Wellenstein MD & de Visser KE (2016) Neutrophils in cancer: neutral no more. Nat Rev Cancer 16, 431–446.
22. Hugo W, Zaretsky JM, Sun L, Song C, Moreno BH, Hu-Lieskovan S, Berent-Maoz B, Pang J, Chmielowski B, Cherry G et al. (2016) Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell 165, 35–44.
23. Germano G, Frapolli R, Belgiovine C, Anselmo A, Pesce S, Liguori M, Erba E, Uboldi S, Zucchetti M, Pasqualini F et al. (2013) Role of macrophage targeting in the antitumor activity of trabectedin. Cancer Cell 23, 249–262.
24. MacDonald KP, Palmer JS, Cronau S, Seppanen E, Olver S, Raffelt NC, Kuns R, Pettit AR, Clouston A, Wainwright B et al. (2010) An antibody against the colony-stimulating factor 1 receptor depletes the resident subset of monocytes and tissue- and tumor-associated macrophages but does not inhibit inflammation. Blood 116, 3955–3963.
25. Ries CH, Cannarile MA, Hoves S, Benz J, Wartha K, Runza V, Rey-Giraud F, Pradel LP, Feuerhake F, Klaman I et al. (2014) Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. Cancer Cell 25, 846–859.
26. Tap WD, Wainberg ZA, Anthony SP, Ibrahim PN, Zhang C, Healey JH, Chmielowski B, Staddon AP, Cohn AL, Shapiro GI et al. (2015) Structure-guided blockade of CSF1R kinase in tenosynovial giant-cell tumor. N Engl J Med 373, 428–437.
27. Ziegler-Heitbrock L (2014) Monocyte subsets in man and other species. Cell Immunol 289, 135–139.
28. Brahmi M, Vinceneux A & Cassier PA (2016) Current systemic treatment options for tenosynovial giant cell tumor/pigmented villonodular synovitis: targeting the CSF1/CSF1R axis. Curr Treat Options Oncol 17, 10.
29. Ries CH, Hoves S, Cannarile MA & Rüttinger D (2015) CSF-1/CSF-1R targeting agents in clinical development for cancer therapy. Curr Opin Pharmacol 23, 45–51.
30. Pahler JC, Tazzyman S, Erez N, Chen YY, Murdoch C, Nozawa H, Lewis CE & Hanahan D (2008) Plasticity in tumor-promoting inflammation: impairment of macrophage recruitment evokes a compensatory neutrophil response. Neoplasia 10, 329–340.
31. Rivera LB, Meyronet D, Hervieu V, Frederick MJ, Bergsland E & Bergers G (2015) Intratumoral myeloid cells regulate responsiveness and resistance to antiangiogenic therapy. Cell Rep 11, 577–591.
32. Quail DF, Bowman RL, Akkari L, Quick ML, Schuhmacher AJ, Huse JT, Holland EC, Sutton JC & Joyce JA (2016) The tumor microenvironment underlies acquired resistance to CSF-1R inhibition in gliomas. Science 352, aad3018.
33. Cassier PA, Italiano A, Gomez-Roca CA, Le Tourneau C, Toulmonde M, Cannarile MA, Ries C, Brillouet A, Muller C, Jegg AM et al. (2015) CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study. Lancet Oncol 16, 949–956.
34. Cannarile MA, Weisser M, Jacob W, Jegg AM, Ries CH & Ruttinger D (2017) Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy. J Immunother Cancer 5, 53.
35. Papadopoulos KP, Gluck L, Martin LP, Olszanski AJ, Tolcher AW, Ngarmchamnanrith G, Rasmussen E, Amore B, Nagorsen D, Hill JS et al. (2017) First-in-human study of AMG 820, a monoclonal anti-colony-stimulating factor 1 receptor antibody, in patients with advanced solid tumors. Clin Cancer Res 23, 5703–5710.
36. Genovese MC, Hsia E, Belkowski SM, Chien C, Masterson T, Thurmond RL, Manthey CL, Yan XD, Ge T, Franks C et al. (2015) Results from a Phase IIA parallel group study of JNJ-40346527, an oral CSF-1R inhibitor, in patients with active rheumatoid arthritis despite disease-modifying antirheumatic drug therapy. J Rheumatol 42, 1752–1760.
37. Recine F, Bongiovanni A, Riva N, Fausti V, De Vita A, Mercatali L, Liverani C, Miserocchi G, Amadori D & Ibrahim T (2017) Update on the role of trabectedin in the treatment of intractable soft tissue sarcomas. Onco Targets Ther 10, 1155–1164.
38. Teplinsky E & Herzog TJ (2017) The efficacy of trabectedin in treating ovarian cancer. Expert Opin Pharmacother 18, 313–323.
39. Hindi N & Martin-Broto J (2017) Current and future systemic treatment options for advanced soft-tissue sarcoma beyond anthracyclines and ifosfamide. Cancer Transl Med 3, 20–28.
40. D'Incalci M & Zambelli A (2016) Trabectedin for the treatment of breast cancer. Expert Opin Investig Drugs 25, 105–115.
41. Michaelson MD, Bellmunt J, Hudes GR, Goel S, Lee RJ, Kantoff PW, Stein CA, Lardelli P, Pardos I, Kahatt C et al. (2012) Multicenter phase II study of trabectedin in patients with metastatic castration-resistant prostate cancer. Ann Oncol 23, 1234–1240.
42. D'Incalci M, Badri N, Galmarini CM & Allavena P (2014) Trabectedin, a drug acting on both cancer cells and the tumour microenvironment. Br J Cancer 111, 646–650.
43. Herrero AB, Martin-Castellanos C, Marco E, Gago F & Moreno S (2006) Cross-talk between nucleotide excision and homologous recombination DNA repair pathways in the mechanism of action of antitumor trabectedin. Cancer Res 66, 8155–8162.
44. Larsen AK, Galmarini CM & D'Incalci M (2016) Unique features of trabectedin mechanism of action. Cancer Chemother Pharmacol 77, 663–671.
45. Allavena P, Signorelli M, Chieppa M, Erba E, Bianchi G, Marchesi F, Olimpio CO, Bonardi C, Garbi A, Lissoni A et al. (2005) Anti-inflammatory properties of the novel antitumor agent yondelis (Trabectedin): inhibition of macrophage differentiation and cytokine production. Cancer Res 65, 2964–2971.
46. Germano G, Frapolli R, Simone M, Tavecchio M, Erba E, Pesce S, Pasqualini F, Grosso F, Sanfilippo R, Casali PG et al. (2010) Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells. Cancer Res 70, 2235–2244.
47. Romano M, la Porta MG, Galli A, Panini N, Licandro SA, Bello E, Craparotta I, Rosti V, Bonetti E, Tancredi R et al. (2017) Antitumour activity of trabectedin in myelodysplastic/myeloproliferative neoplasms. Br J Cancer 116, 335–343.
48. Proudfoot AE, Bonvin P & Power CA (2015) Targeting chemokines: pathogens can, why can't we? Cytokine 74, 259–267.
49. Zhang J, Lu Y & Pienta KJ (2010) Multiple roles of chemokine (C-C motif) ligand 2 in promoting prostate cancer growth. J Natl Cancer Inst 102, 522–528.
50. Lim SY, Yuzhalin AE, Gordon-Weeks AN & Muschel RJ (2016) Targeting the CCL2-CCR2 signaling axis in cancer metastasis. Oncotarget 19, 28697–28710.
51. Fang WB, Yao M, Brummer G, Acevedo D, Alhakamy N, Berkland C & Cheng N (2016) Targeted gene silencing of CCL2 inhibits triple negative breast cancer progression by blocking cancer stem cell renewal and M2 macrophage recruitment. Oncotarget 31, 49349–49367.
52. Fridlender ZG, Kapoor V, Buchlis G, Cheng G, Sun J, Wang LC, Singhal S, Snyder LA & Albelda SM (2011) Monocyte chemoattractant protein-1 blockade inhibits lung cancer tumor growth by altering macrophage phenotype and activating CD8+ cells. Am J Respir Cell Mol Biol 44, 230–237.
53. Fujita M, Kohanbash G, Fellows-Mayle W, Hamilton RL, Komohara Y, Decker SA, Ohlfest JR & Okada H (2011) COX-2 blockade suppresses gliomagenesis by inhibiting myeloid-derived suppressor cells. Cancer Res 71, 2664–2674.
54. Knight DA, Ngiow SF, Li M, Parmenter T, Mok S, Cass A, Haynes NM, Kinross K, Yagita H, Koya RC et al. (2013) Host immunity contributes to the anti-melanoma activity of BRAF inhibitors. J Clin Invest 123, 1371–1381.
55. Moisan F, Francisco EB, Brozovic A, Duran GE, Wang YC, Chaturvedi S, Seetharam S, Snyder LA, Doshi P & Sikic BI (2014) Enhancement of paclitaxel and carboplatin therapies by CCL2 blockade in ovarian cancers. Mol Oncol 8, 1231–1239.
56. Teng KY, Han J, Zhang X, Hsu SH, He S, Wani NA, Barajas JM, Snyder LA, Frankel WL, Caligiuri MA et al. (2017) Blocking the CCL2-CCR2 axis using CCL2-neutralizing antibody is an effective therapy for hepatocellular cancer in a mouse model. Mol Cancer Ther 16, 312–322.
57. Qian DZ, Rademacher BL, Pittsenbarger J, Huang CY, Myrthue A, Higano CS, Garzotto M, Nelson PS & Beer TM (2010) CCL2 is induced by chemotherapy and protects prostate cancer cells from docetaxel-induced cytotoxicity. Prostate 70, 433–442.
58. Yao M, Yu E, Staggs V, Fan F & Cheng N (2016) Elevated expression of chemokine C-C ligand 2 in stroma is associated with recurrent basal-like breast cancers. Mod Pathol 8, 810–823.
59. Pienta KJ, Machiels JP, Schrijvers D, Alekseev B, Shkolnik M, Crabb SJ, Li S, Seetharam S, Puchalski TA, Takimoto C et al. (2013) Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer. Invest New Drugs 31, 760–768.
60. Fetterly GJ, Aras U, Meholick PD, Takimoto C, Seetharam S, McIntosh T, de Bono JS, Sandhu SK, Tolcher A, Davis HM et al. (2013) Utilizing pharmacokinetics/pharmacodynamics modeling to simultaneously examine free CCL2, total CCL2 and carlumab (CNTO 888) concentration time data. J Clin Pharmacol 53, 1020–1027.
61. Dudal S, Subramanian K, Flandre T, Law WS, Lowe PJ, Skerjanec A, Genin JC, Duval M, Piequet A, Cordier A et al. (2015) Integrated pharmacokinetic, pharmacodynamic and immunogenicity profiling of an anti-CCL21 monoclonal antibody in cynomolgus monkeys. MAbs 7, 829–837.
62. Davda JP & Hansen RJ (2010) Properties of a general PK/PD model of antibody-ligand interactions for therapeutic antibodies that bind to soluble endogenous targets. MAbs 2, 576–588.
63. Bonapace L, Coissieux MM, Wyckoff J, Mertz KD, Varga Z, Junt T & Bentires-Alj M (2014) Cessation of CCL2 inhibition accelerates breast cancer metastasis by promoting angiogenesis. Nature 515, 130–133.
64. Keklikoglou I & De Palma M (2014) Cancer: metastasis risk after anti-macrophage therapy. Nature 515, 46–47.
65. Nywening TM, Wang-Gillam A, Sanford DE, Belt BA, Panni RZ, Cusworth BM, Toriola AT, Nieman RK, Worley LA, Yano M et al. (2016) Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial. Lancet Oncol 17, 651–662.
66. Menne J, Eulberg D, Beyer D, Baumann M, Saudek F, Valkusz Z, Wiecek A, Haller H & Emapticap Study, G (2016) C-C motif-ligand 2 inhibition with emapticap pegol (NOX-E36) in type 2 diabetic patients with albuminuria. Nephrol Dial Transplant 2, 307–315.
67. Quezada SA, Jarvinen LZ, Lind EF & Noelle RJ (2004) CD40/CD154 interactions at the interface of tolerance and immunity. Annu Rev Immunol 22, 307–328.
68. Beatty GL, Chiorean EG, Fishman MP, Saboury B, Teitelbaum UR, Sun W, Huhn RD, Song W, Li D, Sharp LL et al. (2011) CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 331, 1612–1616.
69. Long KB, Gladney WL, Tooker GM, Graham K, Fraietta JA & Beatty GL (2016) IFNgamma and CCL2 cooperate to redirect tumor-infiltrating monocytes to degrade fibrosis and enhance chemotherapy efficacy in pancreatic carcinoma. Cancer Discov 6, 400–413.
70. Beatty GL, Li Y & Long KB (2017) Cancer immunotherapy: activating innate and adaptive immunity through CD40 agonists. Expert Rev Anticancer Ther 17, 175–186.
71. Fruman DA & Rommel C (2014) PI3K and cancer: lessons, challenges and opportunities. Nat Rev Drug Discov 13, 140–156.
72. Falasca M & Maffucci T (2014) Targeting p110gamma in gastrointestinal cancers: attack on multiple fronts. Front Physiol 5, 391.
73. De Henau O, Rausch M, Winkler D, Campesato LF, Liu C, Cymerman DH, Budhu S, Ghosh A, Pink M, Tchaicha J et al. (2016) Overcoming resistance to checkpoint blockade therapy by targeting PI3Kgamma in myeloid cells. Nature 539, 443–447.
74. Kaneda MM, Messer KS, Ralainirina N, Li H, Leem CJ, Gorjestani S, Woo G, Nguyen AV, Figueiredo CC, Foubert P et al. (2016) PI3Kgamma is a molecular switch that controls immune suppression. Nature 539, 437–442.
75. Hochreiter-Hufford A & Ravichandran KS (2013) Clearing the dead: apoptotic cell sensing, recognition, engulfment, and digestion. Cold Spring Harb Perspect Biol 5, a008748.
76. Navarro-Alvarez N & Yang YG (2011) CD47: a new player in phagocytosis and xenograft rejection. Cell Mol Immunol 8, 285–288.
77. Weiskopf K (2017) Cancer immunotherapy targeting the CD47/SIRPalpha axis. Eur J Cancer 76, 100–109.
78. Liu X, Pu Y, Cron K, Deng L, Kline J, Frazier WA, Xu H, Peng H, Fu YX & Xu MM (2015) CD47 blockade triggers T cell-mediated destruction of immunogenic tumors. Nat Med 21, 1209–1215.
79. Vonderheide RH (2015) CD47 blockade as another immune checkpoint therapy for cancer. Nat Med 21, 1122–1123.
80. Sikic BI, Narayanan S, Colevas AD, Padda SK, Fisher GA, Supan D, Wakelee HA, Aoki R, Pegram RD, Villalobos VM et al. (2016) A first-in-human, first-in-class phase I trial of the anti-CD47 antibody Hu5F9-G4 in patients with advanced cancers. J Clin Oncol 34, Abstract 3019.
81. Chen J, Zhong MC, Guo H, Davidson D, Mishel S, Lu Y, Rhee I, Perez-Quintero LA, Zhang S, Cruz-Munoz ME et al. (2017) SLAMF7 is critical for phagocytosis of haematopoietic tumour cells via Mac-1 integrin. Nature 544, 493–497.
82. Sarfati M, Fortin G, Raymond M & Susin S (2008) CD47 in the immune response: role of thrombospondin and SIRP-alpha reverse signaling. Curr Drug Targets 9, 842–850.
83. Seiffert M, Brossart P, Cant C, Cella M, Colonna M, Brugger W, Kanz L, Ullrich A & Buhring HJ (2001) Signal-regulatory protein alpha (SIRPalpha) but not SIRPbeta is involved in T-cell activation, binds to CD47 with high affinity, and is expressed on immature CD34(+)CD38(-) hematopoietic cells. Blood 97, 2741–2749.
84. Brown EJ & Frazier WA (2001) Integrin-associated protein (CD47) and its ligands. Trends Cell Biol 11, 130–135.
85. Jeanne A, Schneider C, Martiny L & Dedieu S (2015) Original insights on thrombospondin-1-related antireceptor strategies in cancer. Front Pharmacol 6, 252.
86. Gao L, Chen K, Gao Q, Wang X, Sun J & Yang YG (2016) CD47 deficiency in tumor stroma promotes tumor progression by enhancing angiogenesis. Oncotarget 14, 22406–22413.
87. Azcutia V, Bassil R, Herter JM, Engelbertsen D, Newton G, Autio A, Mayadas T, Lichtman AH, Khoury SJ, Parkos CA et al. (2017) Defects in CD4+ T cell LFA-1 integrin-dependent adhesion and proliferation protect Cd47-/- mice from EAE. J Leukoc Biol 101, 493–505.
88. Van VQ, Baba N, Rubio M, Wakahara K, Panzini B, Richard C, Soucy G, Franchimont D, Fortin G, Torres AC et al. (2012) CD47(low) status on CD4 effectors is necessary for the contraction/resolution of the immune response in humans and mice. PLoS One 7, e41972.
89. Huang Y, Ma Y, Gao P & Yao Z (2017) Targeting CD47: the achievements and concerns of current studies on cancer immunotherapy. J Thorac Dis 9, E168–E174.
90. Kwong LS, Brown MH, Barclay AN & Hatherley D (2014) Signal-regulatory protein alpha from the NOD mouse binds human CD47 with an exceptionally high affinity–implications for engraftment of human cells. Immunology 143, 61–67.
91. Chao MP, Alizadeh AA, Tang C, Myklebust JH, Varghese B, Gill S, Jan M, Cha AC, Chan CK, Tan BT et al. (2010) Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell 142, 699–713.
92. Zhao XW, van Beek EM, Schornagel K, Van der Maaden H, Van Houdt M, Otten MA, Finetti P, Van Egmond M, Matozaki T, Kraal G et al. (2011) CD47-signal regulatory protein-alpha (SIRPalpha) interactions form a barrier for antibody-mediated tumor cell destruction. Proc Natl Acad Sci U S A 108, 18342–18347.
93. Lv Z, Bian Z, Shi L, Niu S, Ha B, Tremblay A, Li L, Zhang X, Paluszynski J, Liu M et al. (2015) Loss of cell surface CD47 clustering formation and binding avidity to SIRPalpha facilitate apoptotic cell clearance by macrophages. J Immunol 195, 661–671.
94. Dheilly E, Moine V, Broyer L, Salgado-Pires S, Johnson Z, Papaioannou A, Cons L, Calloud S, Majocchi S, Nelson R et al. (2017) Selective blockade of the ubiquitous checkpoint receptor CD47 is enabled by dual-targeting bispecific antibodies. Mol Ther 25, 523–533.
95. Piccione EC, Juarez S, Liu J, Tseng S, Ryan CE, Narayanan C, Wang L, Weiskopf K & Majeti R (2015) A bispecific antibody targeting CD47 and CD20 selectively binds and eliminates dual antigen expressing lymphoma cells. MAbs 7, 946–956.
96. Piccione EC, Juarez S, Tseng S, Liu J, Stafford M, Narayanan C, Wang L, Weiskopf K & Majeti R (2016) SIRPalpha-antibody fusion proteins selectively bind and eliminate dual antigen-expressing tumor cells. Clin Cancer Res 22, 5109–5119.
97. Yanagita T, Murata Y, Tanaka D, Motegi SI, Arai E, Daniwijaya EW, Hazama D, Washio K, Saito Y, Kotani T et al. (2017) Anti-SIRPalpha antibodies as a potential new tool for cancer immunotherapy. JCI Insight 2, e89140.
98. Chevrier S, Levine JH, Zanotelli VRT, Silina K, Schulz D, Bacac M, Ries CH, Ailles L, Jewett MAS, Moch H et al. (2017) An immune atlas of clear cell renal cell carcinoma. Cell 169, 736–749.e18.
99. Lavin Y, Kobayashi S, Leader A, Amir ED, Elefant N, Bigenwald C, Remark R, Sweeney R, Becker CD, Levine JH et al. (2017) Innate immune landscape in early lung adenocarcinoma by paired single-cell analyses. Cell 169, 750–765.e17.
100. Gao J, Ward JF, Pettaway CA, Shi LZ, Subudhi SK, Vence LM, Zhao H, Chen J, Chen H, Efstathiou E et al. (2017) VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer. Nat Med 23, 551–555.
101. Tsujikawa T, Kumar S, Borkar RN, Azimi V, Thibault G, Chang YH, Balter A, Kawashima R, Choe G, Sauer D et al. (2017) Quantitative multiplex immunohistochemistry reveals myeloid-inflamed tumor-immune complexity associated with poor prognosis. Cell Rep 19, 203–217.